BELEAN.NET: We are part-time CFO for start-ups and scale-ups in biotech and digital. We support companies in strategy, fundraising, M&A, Due Diligence, business modelling, financial controlling, implementation of internal processes and ERP. MISSION: Supported by the partners and seniors of beLean.net, you participate directly in the various CFO missions. YOU: You are passionated about start-ups and technology and you[…]
A first-round funding of 3 millions euros has been raised by Vésale Bioscience, the spin-out of the Vésale Pharma group which focuses on phagotherapy. In order to increase its financial resources and reach the stock market, the group has hired beLean.net Partner Guillaume de Viron as Head of Finance for the phage therapy division. Co-founder of Univercells, former CFO of MaSTHerCell,[…]
Vésale Bioscience has hired Guillaume de Viron, Partner at beLean.net, as Chief Financial Officer in order to accelerate its IPO. As CFO, Guillaume de Viron will contribute to Vésale Bioscience, which is currently preparing its fundraising (10+ million €) with the aim of accelerating the production and marketing of phages. Phage therapy is the use of phages,[…]
Pharmaceutical companies used to be eager buyers of technology. But in recent years, biotech platforms have benefited from easier access to capital as independent entities, eliminating the need to sell. At the same time, biopharma companies large and small are realizing that building a platform is better than focusing on a single product or production[…]
Imcyse raises €21M and opens its capital to its new American partner, Pfizer. Very good news for the Liège-based biotech company Imcyse. Indeed, the biotech has developed an active immunotherapy technology that allows to tackle autoimmune diseases such as multiple sclerosis, type 1 diabetes or rheumatoid arthritis. A licensing agreement has just been signed with[…]
The Walloon Region Government to support the development of treatments at Novadip with 9.4M€ of non-dilutive funding Novadip Biosciences, a clinical-stage company developing treatments to regenerate damaged tissues in patients with significant unmet medical needs, has announced that the US Food and Drug Administration (FDA) has granted the designation of Rare Pediatric Disease and Orphan[…]
OUAT! recently raised 500k€ with the Innovation Fund. The capital infusion will support the further development of HakoBio and the roll out of the software to new clients. OUAT! aims to facilitate the digital transformation of the life sciences industry. In increasingly intelligent and connected factories, OUAT! enables the men and women of the biopharmaceutical industry to achieve[…]
Univercells Holding recently raises €70 million with two rounds of capital increase with new investors. The capital infusion will support the development of GMP facilities and the capacity to foster distributed manufacturing and supply of biologics. Univercells recently completed their Series C second close, bringing the total raised to €70 million. The financing, which was over-subscribed,[…]
Many large investors have already set their sights on the Walloon company Univercells. Among them stands out the American billionaire George Soros; famous financier and philanthropist at the age of 90, Adjuvant Capital; a fund linked to the Bill Gates galaxy, the federal government through SFPI, and the Walloon government through SRIW. Bill Gates, as[…]
Univercells has just completed a new funding round of around 50 million €. Among its investors, a fund linked to the Bill & Melinda Gates Foundation, which has already helped the Walloon biotech on several occasions. The list of investors includes Adjuvant Global Health Technology Fund, a fund originally linked to the Bill & Melinda Gates Foundation, which[…]
BRUSSELS, BELGIUM – FEBRUARY 18,2020 — Univercells, an innovative bioprocessing provider focused on increasing the availability of affordable biologics to address global health challenges, has announced up to EUR 50M financing from Gamma Biosciences, a new investment platform supported by leading global investment firm KKR, that is focused on next-generation bioprocessing technologies for the production of advanced[…]
GOSSELIES, BELGIUM – FEBRUARY 14TH, 2020 — OncoDNA (“OncoDNA or “the Company”), the healthcare technology company making precision medicine a reality, today announced that it has completed a €19 million ($20 million) Series B equity financing. The new funding will support rapid international growth, accelerate software development and hiring initiatives. The round was led by Vesalius Biocapital[…]
Liège, Belgium and Grenoble, France, January 22, 2020 – PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, announces today the completion of its Series B round of financing. The company has raised a total of €20 million ($22.2M). Two and a half years after its last round of[…]
Proud to have helped Imcyse to fundraise 35M€ to carry out clinical trials of treatments for type 1 diabetes, multiple sclerosis and other autoimmune diseases. Please read the article in L’Echo: https://www.lecho.be/entreprises/pharma-biotechnologie/imcyse-se-profile-comme-la-future-pepite-wallonne-de-la-biotech/10137301.html Imcyse secures total of €35M in Series B financing round and additional grants
Our customer Univercells has been awarded a $12 Million grant by the Bill & Melinda Gates Foundation to develop a breakthrough vaccine manufacturing platform. Its aim is to drastically reduce the cost of vaccines whilst increasing their availability and affordability in developing countries. « Humanity’s greatest advances are not in its discoveries, but in how those discoveries[…]
Our customer Univercells partners with Takeda Pharmaceutical Company Limited to produce affordable vaccines for All. Press release: http://www.univercells.com/newsroom/univercells-partners-takeda/